Long-Term Value
Building sustainable shareholder value through focused ownership and strategic development.
Stockholm · Long-Term Ownership
Building lasting value
through pharmaceutical
innovation
Captigenics Capital is a Swedish investment company and majority owner of Auxesis Pharma Holding AB (publ), supporting the development and international commercialization of patented topical treatments.
Active
Majority Ownership
Long-Term
Investment Strategy
Patented
Technology Platform
Global
Growth Ambition
Who We AreFocused ownership for
Focused ownership for
long-term pharmaceutical innovation
We invest in science, innovation and long-term value creation
Captigenics Capital is a Swedish investment company focused on long-term ownership and value creation within the pharmaceutical sector.
Our primary holding is Auxesis Pharma Holding AB (publ), a Swedish pharmaceutical company developing patented topical treatments for local skin pain, irritation and dermatological conditions.
Through active ownership, Captigenics supports Auxesis Pharma's strategic development, financing and international growth. The company's commercial strategy is built around clinical validation, licensing, strategic partnerships and expansion into global markets.
Stockholm
Based in Sweden
Auxesis Pharma
Primary Holding
Life Sciences
Investment Focus
Active Ownership
Supporting governance, financing and the long-term development of Auxesis Pharma.
International Ambition
Supporting global growth through licensing, partnerships and market expansion.
Science-Led Innovation
Backing patented technology and product development grounded in scientific research.
Strategic Investment
Our flagship holding — Auxesis Pharma
Captigenics Capital's primary investment is Auxesis Pharma, a Swedish pharmaceutical company developing patented topical therapies for local skin pain, irritation and dermatological conditions.
Built on The Pain Block™ technology, Auxesis combines pharmaceutical innovation, dermatology and veterinary medicine within a scalable platform designed for international commercialization through licensing, strategic partnerships and global market expansion.
Patented Technology
One platform enabling multiple commercial products
5+ Product Brands
A diversified pharmaceutical and dermatology portfolio
Global Opportunity
International growth through licensing and partnerships
Investor Relations
Annual Reports
Transparent reporting on performance, governance, and strategy. Download our official annual reports below.
Contact
Contact Captigenics
If you have questions about Captigenics, our ownership in Auxesis Pharma, or would like to get in touch with our team, please send us a message.
Location
Stockholm, Sweden